Pancreatic cancer is one of the most deadly types of malignancies, with a 5-year survival rate after late diagnosis of only about 5%. The majority of patients—about 80%—receive their diagnosis too late for surgery. The disease spreads quickly and resists chemotherapy. In short, there is an urgent need for diagnostic tools to identify this cancer in its earliest stages.
A Fred Hutchinson Cancer Research Center study, led by epidemiologist Dr. Parveen Bhatti, found that night shift work is associated with reduced ability to repair DNA lesions. Over time, DNA damage that is not repaired will cause mutations that can lead to cancer.
Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH and a developer of pioneering solutions for the detection of genetic resistances in pathogens, announced that the project "GEAR - Predicting Antibiotic Resistances with Genetic Data" has been awarded in the competition "Landmarks in the Land of Ideas".
Cancer biomarker testing represents an important element of the clinical biochemistry service, yet progress in this area in the last two decades has been slow.
For almost three quarters of hepatocellular carcinoma (HCC) patients in Europe it is too late for curative treatment because the disease is often only diagnosed at a very advanced stage. Interviewed Professor Guido Gerken MD, Director of the Department for Gastroenterology and Hepatology at University Hospital Essen, about improved and timelier diagnostic capabilities that have already been…
Glaucoma, a leading cause of blindness worldwide, most often is diagnosed during a routine eye exam. Over time, elevated pressure inside the eye damages the optic nerve, leading to vision loss. Unfortunately, there’s no way to accurately predict which patients might lose vision most rapidly. Now, studying mice, rats and fluid removed from the eyes of patients with glaucoma, researchers at…
The one-size-fits-all approach to early stage breast cancer creates a paradox: Millions of dollars are spent on unnecessary surgeries and radiation to treat women with low-risk ‘in situ’ lesions, an estimated 85% of which would never progress to invasive cancers. Meanwhile, the standard conservative treatment is insufficient for many early-stage tumors that have progressed past the in situ…
About six years ago, liquid biopsy appeared on the diagnostic lab stage. Last December, a seminar offered by Agena Bioscience in Frankfurt, Germany, was set to explore the enormous potential of this new technique for oncology.
Methyl labels in the DNA regulate the activity of our genes and, thus, have a great influence on health and disease. Scientists from the German Cancer Research Center and from the Saarland cancer registry have now revealed that an altered methylation status at only ten specific sites in the genome can indicate that mortality is increased by up to seven times. Smoking has a particularly…
Our knowledge of causes and mechanisms of current and future diseases is on ice – not the perpetual ice of the polar caps but artificial ice. It is stored in biobanks at -80 to -160 °C.
To treat or not to treat? That is the question researchers at the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) hope to answer with a new advance that could help doctors and their cancer patients decide if a particular therapy would be worth pursuing.
People with high levels of four biomarkers in the blood may be more likely to develop a stroke than people with low levels of the biomarkers, according to a study published in the August 24, 2016, online issue of Neurology®, the medical journal of the American Academy of Neurology.
It’s well known that cardiovascular disease (CVD) is the leading cause of death in the UK and worldwide. In the UK it is responsible for more than 73,000 deaths annually, affecting 1 in 6 men and 1 in 10 women. With the emergence of such startling statistics, this begs the question, why do routine cholesterol tests still rely on the basic biomarkers high density lipoprotein (HDL), low density…
As part of a national, joint research project in cooperation with Chronix Biomedical (San Jose, CA/USA/Göttingen/Germany), Professor Michael Oellerich MD is on new biomarkers in organ transplantation, aiming to develop personalised immunosuppression for patients. This also entails the development of molecular test procedures, among others for the early detection of rejection. The keyword here is…
When a woman is diagnosed with the earliest stage of breast cancer, how aggressive should her treatment be? Will the non-invasive cancer become invasive? Or is it a slow-growing variety that will likely never be harmful? Researchers at the University of Michigan developed a new technology that can identify aggressive forms of ductal carcinoma in situ, or stage 0 breast cancer, from non-aggressive…
Harnessing the potential of digital pathology is taking research into new and more efficient biomarkers to a new level. By combining strategic planning with the latest digital pathology technology, high quality tissue microarrays for biomarker research are being produced.
Accurate diagnosis of Parkinson's disease, and the related disease "dementia with Lewy bodies," can be difficult in the early stages of both conditions. While brain biopsies can be more accurate, the risk of complications has been considered too high.
MedUni Vienna researchers have published the results of a clarifying research study on the potential transmissibility of Alzheimer’s disease. Although the protein associated with Alzheimer’s disease, amyloid-β, might be transmissible under very unusual circumstances, this does not go along with a transmission of the clinical manifestation of Alzheimer’s disease. The affected persons…
Randox Quality Control are pleased to announce, as part of our ongoing growth and development, the launch of our new Acusera Calibration Verification range for Beckman and Roche Cobas instruments.
‘In imaging there is a trend towards quantification,’ said Professor Siegfried Trattnig, Medical Director of the High-Field MR Centre (HFMRC) at the Medical University Vienna, Austria. Whilst before, radiologists’ findings were subjective, qualitative results, based on signal intensity and grey scale, he pointed out. ‘Today imaging can draw on quantifiable and comparable parameters with…
Personalised medicine relies strongly on biobanking in which medical data are collected on a large scale. Large scale refers both to the amount of data collected per patient as well as to the large number of patients included in the data collection. Although most attention in biobanking has been given to genetic data, proteomics, metabolomics and other –omics technologies, imaging is also being…
Royal Philips and Banyan Biomarkers, Inc. today announced that they have entered into a multi-year joint development agreement to develop and commercialize a new handheld blood test to detect and evaluate mild traumatic brain injury (TBI) - also known as concussion - at the point of care. The new handheld test will be based on Philips’ Minicare I-20 system. The financial details of the…
Patients with multiple sclerosis often receive a "hit and miss" treatment when the disease breaks out. A blood analysis is now for the first time able to reveal which of the two most important first-line drugs is better suited for which patients.
More than five million Americans are living with Alzheimer's disease (AD). Of them, 400,000 also have Down syndrome. Both groups have similar looking brains with higher levels of the protein beta amyloid.
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, UK researchers have found. The discovery could lead to a non-invasive, inexpensive test to screen people at high risk of developing the disease.